---
title: "Cellectar 生物科学的 Iopofosine I 131 用于复发或难治性儿科高级别胶质瘤，获得了美国食品药品监督管理局的罕见儿科疾病认定"
description: "新泽西州弗洛汉公园，2025 年 10 月 27 日（GLOBE NEWSWIRE）-- Cellectar 生物科学公司（NASDAQ:CLRB），一家专注于癌症治疗药物发现和开发的晚期临床生物制药公司，今天宣布了美国的消息"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/262917853.md"
published_at: "2025-10-27T13:37:57.000Z"
---

# Cellectar 生物科学的 Iopofosine I 131 用于复发或难治性儿科高级别胶质瘤，获得了美国食品药品监督管理局的罕见儿科疾病认定

> 新泽西州弗洛汉公园，2025 年 10 月 27 日（GLOBE NEWSWIRE）-- Cellectar 生物科学公司（NASDAQ:CLRB），一家专注于癌症治疗药物发现和开发的晚期临床生物制药公司，今天宣布了美国的消息

FLORHAM PARK, N.J., Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Cellectar Biosciences, Inc. ( NASDAQ:CLRB ) , a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the U.S.

### Related Stocks

- [CLRB.US - Cellectar生物科学](https://longbridge.com/zh-CN/quote/CLRB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Oppenheimer Remains a Hold on Cellectar Biosciences (CLRB) | Cellectar Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $15.20. | [Link](https://longbridge.com/zh-CN/news/259777975.md) |
| Cellectar BioSciences Partners with Ionetix for Alpha-Emitting Isotope Supply | Cellectar BioSciences Inc. has partnered with Ionetix Corporation in a multi-year agreement to secure supplies of alpha- | [Link](https://longbridge.com/zh-CN/news/269868087.md) |
| Significant opportunities exist in the global pain market for novel mechanisms and modalities | The global pain market presents significant opportunities for innovation, particularly in developing non-addictive alter | [Link](https://longbridge.com/zh-CN/news/275921122.md) |
| James Van Der Beek Warned of the 1 Telling Cancer Symptom He Had Months Before His Death: ‘I Had No Idea… ‘ | James Van Der Beek, known for his roles in Dawson’s Creek and Varsity Blues, passed away at 48 from colorectal cancer. H | [Link](https://longbridge.com/zh-CN/news/275956382.md) |
| ZAWYA-PRESSR: Burjeel Medical City launches Sarcoma & Bone Center to strengthen care for rare and complex cancers | Burjeel Cancer Institute has launched a specialized Sarcoma & Bone Center at Burjeel Medical City in Abu Dhabi, enhancin | [Link](https://longbridge.com/zh-CN/news/275995782.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。